The US House Energy & Commerce Health Subcommittee unveiled 15 bills and discussion drafts to reform the 340B prescription drug discount program at a hearing July 11 in an effort to develop consensus on the best approach to enhancing oversight.
The session builds on the hearings held over the past two years by the Energy & Commerce Oversight & Investigations Subcommittee, which culminated with a report in early 2018 recommending increased government oversight for the program. (Also see "340B Provider Reforms Gaining Momentum In Congress" - Pink Sheet, 12 January, 2018.) A key Senate committee has also held hearings on 340B reform
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?